Drugmakers raised list prices on more than 350 branded medications at the start of 2026, with a median increase of about 4% and some hospital-administered drugs climbing by multiples. Health system operating margins sit at roughly 1.5%. The 340B program, responsible for $81.4 billion in purchases as recently as 2024, faces a potential rebate model overhaul that could upend pharmacy cash flow overnight.
All of these hurdles land on procurement teams who are already navigating 2,500 preferred NDCs, 10,000+ weekly price updates, and 270+ active drug shortages at any given time. The old approach of managing pharmacy purchasing, supply continuity, and compliance in separate workflows no longer holds. Every NDC selection now carries financial, regulatory, and operational consequences that compound across a health system.
What’s Changed at the NDC Level
The 340B rebate pilot – regardless of when it might go into effect – represents a structural shift in how covered entities will pay for medications. If and when the model is finalized and approved, hospitals will front full WAC costs and wait for manufacturer reimbursements, creating temporary drug spend spikes of 500% to 5,000% during the submission window. That single change transforms every NDC decision from a procurement transaction into a cash flow event.
Layer in the Medicare Drug Price Negotiation Program, rolling out additional negotiated drugs in 2027, and the financial variables attached to each NDC multiply further. Specialty drugs now represent more than half of total pharmaceutical expenditures despite serving a small fraction of the patient population, concentrating financial risk into fewer line items.
The Three Pillars of NDC-Level Contract Compliance
Today, pharma inventory management requires lifecycle cost analysis that weighs acquisition price against rebate certainty, supply stability, and compliance risk before a single purchase order goes through.
NDC-level contract compliance comprises three interconnected areas:
- Drug spend optimization
- Supply continuity
- 340B program integrity
Gaps in any one of them create risk in the other two.
Optimize Drug Spend at the NDC Level
Invoice inaccuracies alone account for significant hidden losses. Pricing misloads, duplicate charges, and wholesaler billing errors routinely slip through manual review processes.
Individual overcharges can exceed $100,000 before anyone catches them, and without a systematic workflow for flagging, submitting, and tracking corrections, those dollars are gone. NDC-level pharmacy purchasing compliance means real-time contract alignment monitoring, automated identification of lower-cost equivalent NDCs, and benchmarking against market pricing across primary and secondary wholesalers.
Bluesight’s 2025 Purchasing Trends Report found that nearly 500 hospitals using CostCheck saved over $100 million as of July 2025 through recommended NDC changes and automated contract management.
Protect Supply Continuity Before Shortages Hit
Drug shortages have shifted from temporary disruptions to a persistent operational burden. ASHP tracked a record 323 active shortages in early 2024, and 70% of pharmacy teams now manage 10 or more shortages concurrently.
Managing these gaps consumes an average of 24 hours of pharmacy labor per week, time pulled directly from patient care and clinical optimization.
Off-contract purchasing at premium prices, costly outsourcing to compounding facilities, and clinical disruptions all trace back to the same root cause: reacting to shortages after they hit, instead of before.
In ASHP’s most recent survey, 99% of respondents reported experiencing a drug shortage, with 32% reporting that shortages forced rationing, delaying, or canceling treatment.
NDC-level inventory control hospital pharmacy teams need includes:
- Predictive shortage alerts tied to the specific NDCs your facility actually purchases, not generic industry-wide notifications
- Financial impact modeling for alternative NDCs, so switching decisions account for cost, supply stability, and contract compliance simultaneously
- Early warning windows are measured in weeks, not days. Bluesight’s ShortageCheck provides up to 90 days of lead time on predicted shortages, giving hospitals time to adjust protocols, secure alternatives, and communicate changes to prescribers
Maintain 340B Compliance at Every Transaction
In FY 2024, 62% of HRSA audits cited incorrect OPAIS records, and 18% required repayment to manufacturers. Most covered entities still audit fewer than 25% of their transactions.
The gap between what gets checked and what gets missed represents real financial exposure, especially as HRSA intensifies its focus on complex diversion findings like prescriptions written at unregistered sites or through non-compliant contract pharmacies.
Effective pharma inventory management at the 340B level requires:
- 100% transaction auditing, not sampling. Every dispense, administration, waste, and return must reconcile against purchase records at the NDC level.
- Real-time split-billing validation to catch errors like missing UD modifiers before they become duplicate discount violations.
- NDC-level matching between purchase and dispense data, so accumulator records stay defensible against both federal and manufacturer scrutiny.
The stakes are steep. A single adverse HRSA audit finding can trigger repayment demands, increased audit frequency, and in cases of systemic violations, removal from the program entirely.
Putting It Into Practice
Most pharmacy teams understand the risks of contract misalignment, off-contract purchasing, and 340B recordkeeping gaps. Fewer have a repeatable process for catching and correcting those issues before they become losses.
A practical compliance workflow starts with three operational habits:
- Establish a Weekly NDC Review Cadence
Designate a recurring block, even 30 minutes, for a pharmacy buyer or analyst to review flagged contract misalignments, pricing anomalies, and recommended NDC changes. The goal is not to audit every line item manually. It is to act on the highest-impact exceptions that automated monitoring surfaces each week.
Teams that build this into their weekly rhythm convert procurement software from a reporting tool into a decision-making engine. A 14-hospital system achieved $3.5 million in savings with only a few hours per week in CostCheck, because the workflow was built around triaging prioritized alerts, not reviewing raw data.
- Triage NDC Changes Against All Three Pillars Before Executing
Every proposed NDC switch should pass through a three-part check before a purchase order is placed:
- Cost: Does the alternative NDC reduce acquisition cost, and does the savings hold after accounting for GPO compliance and 340B rebate eligibility?
- Supply: Is the alternative NDC at risk of shortage? Are there early warning signals from purchasing trend data or wholesaler fulfillment patterns?
- Compliance: Does the switch affect your 340B split-billing configuration, accumulator alignment, or OPAIS registration?
Running these checks in sequence adds minutes to a procurement decision. Skipping them can cost weeks of remediation, lost rebates, or audit exposure.
Build Cross-Functional Visibility Into Procurement Decisions
Pharmacy purchasing decisions affect finance, compliance, and clinical operations. Yet in many health systems, the buyer making the NDC switch has no visibility into 340B accumulator status, and the 340B analyst has no visibility into why a product was changed.
Breaking these silos does not require reorganizing departments. It requires shared access to the same data. When the procurement team, the 340B compliance team, and the shortage management team can see the same NDC-level information, each decision reinforces the others instead of creating downstream surprises.
From Siloed Decisions to Unified Procurement Intelligence
A procurement team switches to a lower-cost NDC to save on spend, only to discover weeks later that the product is entering a long-term shortage. Or an NDC change inadvertently triggers a 340B non-compliance finding because the new product falls outside the facility’s registered pricing tier.
These cascading failures happen when cost, supply, and compliance decisions live in separate workflows.
| Siloed Approach | Unified Approach |
| NDC selected on lowest acquisition cost alone | NDC evaluated against price, supply forecast, and 340B impact before purchase |
| Shortage response is reactive, often at premium pricing | Predictive alerts flag at-risk NDCs weeks before formal shortage announcements |
| 340B compliance reviewed in periodic snapshots | Every transaction audited continuously in real time |
| Contract mismatches discovered after rebate deadlines pass | Misalignments flagged and corrected proactively across all facilities |
Bluesight’s procurement intelligence suite, CostCheck, ShortageCheck, and 340BCheck, connects these three pillars so that data flows between them. The result is procurement decisions that account for price, availability, and audit readiness simultaneously:
- Up to 4% in drug spend savings through NDC-level cost optimization across primary and secondary wholesalers
- Up to 90-day lead time on shortage predictions, giving teams time to secure alternatives and adjust protocols before supply gaps hit
- 340B audit prep shortened by 45 days, shifting compliance from periodic snapshots to continuous validation
Turning NDC Decisions Into Strategic Advantage
Pharmacy teams that treat every NDC selection as a strategic decision, one that touches finance, supply chain, and compliance at once, will protect margins and maintain audit readiness as the regulatory environment tightens.
Those still managing these functions in isolation will continue absorbing preventable losses.
Schedule a demo to see how Bluesight connects cost, supply, and compliance decisions at the NDC level, so your team can act with confidence on every purchase.